Advice

Following a full submission

clostridium botulinum neurotoxin type A (Xeomin) is accepted for use within NHS Scotland for the symptomatic management of blepharospasm and cervical dystonia of a predominantly rotational form (spasmodic torticollis) in adults.

For both indications, a similar improvement in symptoms has been shown compared to another clostridium botulinum neurotoxin type A.

Download detailed advice87KB (PDF)

Download

Medicine details

Medicine name:
botulinum neurotoxin type A (Xeomin)
SMC ID:
464/08
Indication:
symptomatic management of blepharospasm and cervical dystonia of a predominantly rotational form (spasmodic torticollis) in adults
Pharmaceutical company
Merz Pharma UK Ltd
BNF chapter
Central nervous system
Submission type
Full
Status
Accepted
Date advice published
09 June 2008